Sonia Maria Poli
Director/Board Member bei DIMERIX LIMITED
Vermögen: 76 820 $ am 31.03.2024
Profil
Sonia Maria Poli is currently an Independent Non-Executive Director at Dimerix Ltd., a Managing Director & Director at Dimerix Bioscience Pty Ltd., an Executive Manager at AC Immune SA, and the Chief Scientific Officer at Minoryx Therapeutics SL.
Previously, she worked at F.
Hoffmann-La Roche Ltd.
as the Global Head-Multidimensional Optimization and at Addex Therapeutics Ltd.
as the Vice President-Translational Science.
Dr. Poli obtained her graduate and doctorate degrees from the University of Milan.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
DIMERIX LIMITED
0,07% | 31.03.2024 | 392 500 ( 0,07% ) | 76 820 $ | 31.03.2024 |
Aktive Positionen von Sonia Maria Poli
| Unternehmen | Position | Beginn |
|---|---|---|
| DIMERIX LIMITED | Director/Board Member | 03.07.2015 |
| AC IMMUNE SA | Corporate Officer/Principal | 01.09.2017 |
Dimerix Bioscience Pty Ltd.
 Dimerix Bioscience Pty Ltd. Medical DistributorsDistribution Services Dimerix Bioscience Pty Ltd. engages in the development and commercialization of drug therapies and drug discovery tools. It deals with clinical research organizations to progress its programs through clinical studies. It focuses on the clinical development of its therapeutic product DMX200 which is targeted to treat patients with chronic kidney disease. The company was founded by James Howard Williams on December 16, 2004 and is headquartered in Melbourne, Australia. | Chief Executive Officer | 01.05.2014 |
Minoryx Therapeutics SL
 Minoryx Therapeutics SL BiotechnologyHealth Technology Minoryx Therapeutics SL engages in the development of drugs for the orphan genetic diseases of the central nervous system. The company was founded by Marc Martinell, Joan Aymami, Nigel Ten Fleming and Xavier Barril in 2011 and is headquartered in Barcelona, Spain. | Chief Tech/Sci/R&D Officer | 01.08.2019 |
Ehemalige bekannte Positionen von Sonia Maria Poli
| Unternehmen | Position | Ende |
|---|---|---|
| ADDEX THERAPEUTICS LTD | Chief Tech/Sci/R&D Officer | 18.09.2017 |
F. Hoffmann-La Roche Ltd.
 F. Hoffmann-La Roche Ltd. Pharmaceuticals: MajorHealth Technology F. Hoffmann-La Roche Ltd. manufactures pharmaceutical products. It offers pharmaceutical drugs, pharmaceutical instruments, and diagnostics solutions. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland. | Corporate Officer/Principal | 01.01.2004 |
Ausbildung von Sonia Maria Poli
| University of Milan | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 3 |
|---|---|
| AC IMMUNE SA | Health Technology |
| ADDEX THERAPEUTICS LTD | Health Technology |
| DIMERIX LIMITED | Health Technology |
| Private Unternehmen | 3 |
|---|---|
F. Hoffmann-La Roche Ltd.
F. Hoffmann-La Roche Ltd. Pharmaceuticals: MajorHealth Technology F. Hoffmann-La Roche Ltd. manufactures pharmaceutical products. It offers pharmaceutical drugs, pharmaceutical instruments, and diagnostics solutions. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland. | Health Technology |
Dimerix Bioscience Pty Ltd.
Dimerix Bioscience Pty Ltd. Medical DistributorsDistribution Services Dimerix Bioscience Pty Ltd. engages in the development and commercialization of drug therapies and drug discovery tools. It deals with clinical research organizations to progress its programs through clinical studies. It focuses on the clinical development of its therapeutic product DMX200 which is targeted to treat patients with chronic kidney disease. The company was founded by James Howard Williams on December 16, 2004 and is headquartered in Melbourne, Australia. | Distribution Services |
Minoryx Therapeutics SL
Minoryx Therapeutics SL BiotechnologyHealth Technology Minoryx Therapeutics SL engages in the development of drugs for the orphan genetic diseases of the central nervous system. The company was founded by Marc Martinell, Joan Aymami, Nigel Ten Fleming and Xavier Barril in 2011 and is headquartered in Barcelona, Spain. | Health Technology |
